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Abstract--In this paper, we present a stochastic inventory model for monoclonal antibody maintenance 
and production during a secondary immune response. This involves a new concept of "cost" factors to 
represent associated biochemical energy constraints/n vivo. Analysis and illustrative results for predictive 
and explanatory applications are also presented and future directions of research indicated. 
1. INTRODUCTION 
With the objective of elucidating some important, experimentally unobservable, features of the 
immune system, here, we present an inventory model and analysis of the antibody production 
system. After introducing some relevant immunological aspects, we consider the associated 
theoretical developments in successive sections. We also discuss the biological significance of this 
analysis, along with an interpretation of the numerical results. 
I.I. The Immune Response 
When antigens enter a normal immune system, they are recognized and bound by their specific 
antibodies, which eventually leads to their destruction. If the binding antibody is B-cell bound, 
the B-cell is either stimulated or paralysed. The B-cell fails to react when the concentration of 
antigens is either too low (low-zone tolerance) or too high (high-zone tolerance). On the other hand, 
stimulated B-cells differentiate into resting and plasma cells and produce antibodies of the 
associated specificity. Plasma cells rapidly produce large quantities of the specific antibodies while 
the resting cells retain a "memory" of the attack and mount a quick response to later exposures 
to antigens of the same type. Antibodies of other specificities are also produced, possibly as a result 
of a chain reaction through the lymphatic network. 
It appears that an individual immune system possesses an almost limitless antibody repertoire 
and can deal with any antigen occurring in nature (Coutinho et al., 1984). It is thought (Jerne, 1985) 
that it contains a few chosen specificities, from which any other required type is synthesized by 
(probably) a trial-and-error method when a need is encountered. However, the error-free regulation 
of different physiological functions of enormous complexity and the ideal maintenance of 
biochemical energy in higher organisms do not seem to be so efficiently governed by just a 
trial-and-error mechanism. The selection of specificities should be based on some optimizing 
principle. With this proposition we investigate some important features of the antibody production 
system. 
1.2. Inventory Model for Antibody Production 
With advanced investigations and better understanding of the immune system, the theoretical 
fields connected with its many aspects have been growing rapidly. Despite differences at the 
physiological nd molecular or biochemical levels in the mode of stimulation of the immune system 
for different ypes of antigens, a common and significant feature of a normal immune response 
which interests us here is that, at least after the first non-paralysing exposure to antigens of a 
specificity (e.g. after vaccination), there is always a stock of the specific antibodies and their 
producing lymphocytes in the repertoire of the immune system of the living organism. The retention 
of such stocks should necessarily be performed in such a way that a balance in the allocation of 
the available biochemical energy for the conflicting needs of different bodily functions is 
maintained. Considering these factors, a number of interesting questions arise, the answers to which 
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may lead to the elucidation of significant features of the immune system. Some of these questions 
can be formulated as follows: 
(1) How many and which specificities of antibodies does an individual's immune 
system inherit from the parents? 
(2) How many antibodies of each of the chosen kinds will be maintained in stock? 
(3) What would their numbers be after an immune response to a known/unknown 
antigen? 
(4) What would be the price paid in terms of tissue damage, sudden demand on 
available nergy for discovering the correct mix of amino acids that will form 
the required specific antibody etc., due to an absence of antibodies of the correct 
specificity to an antigen, in the immune system? 
We can investigate for possible answers to these questions by inventory analysis. 
1.2.1. Inventory 
In econometrics, the term "inventory" is used to describe a physical stock of goods that is 
maintained with a view to satisfying future demand. "Inventory level" refers to the quantity of the 
product that is currently in stock. Inventory modelling mainly involves optimization of the 
inventory level subject o certain cost considerations. When an inventory of more than one product 
is maintained, it is called a multiproduct inventory system (Wagner, 1974). In the immune system, 
the antibody of each specificity can be considered to be a "product". The number of antibodies 
of each specificity that are maintained in stock corresponds to the inventory level in the 
multiproduct situation. For instance, if there are n, antibodies of the ith specificity in stock 
( i= 1,2 . . . . .  m), the multiproduct inventory level may be represented as the vector 
n = (n l ,  n2 ,  • • • ,  nm) .  
1.2.2. Demand 
The main purpose in maintaining an inventory is that of satisfying future demand in such a way 
as to maximize customers' convenience without loss to the supplier. The demand may be in the 
form of raw material or intermediate product requirements by the company itself, or it may be 
external. In the immune system, we consider demand to be the presence of unbound antigens: 
self-antigens constitute an internal demand while external demand involves foreign antigens. 
In economic systems, the quantity that will be demanded may be known either accurately 
(deterministic models) or according to some probability law (stochastic models). Further, demand 
may be either discrete or continuous. In the immune system, taking the quantity demanded to be 
the number of unbound antigens, demand would be discrete. Since, even in the case of vaccinations 
where a "known" concentration of antigens is introduced, the number of antigens entering the 
system would vary randomly, demand is necessarily probabilistic in nature. 
Consider the case of introduction of a single type of antigen into the immune system. According 
to the network hypothesis, this disturbs the equilibrium of the system. In order to regain 
equilibrium, specific antibodies are produced to meet the demand. This leads to initiation of 
"demand" for anti-iodiotypic antibodies to the specific antibodies (self-antigens), and thence, 
anti-anti-idiotypic antibodies, and so on, till the balance is restored. In this respect, the immune 
system differs from the usual inventory models. It can be likened to the economy of a 
pharmaceutical ompany which produces drugs having harmful side-effects hat can be overcome 
by the administration f other drugs, also produced by the same company. 
1.2.3. Costs 
Holding of an inventory incurs a cost due to the cost of storage space, security arrangements, 
loss due to spoilage tc. Antibody holding costs in the immune system would be in terms of the 
effect of the antibody on the physical system through its interactions with other bodily components, 
the extra biochemical energy consumption from body resources for its maintenance and the 
likelihood of autoimmunity etc. 
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In the economic situation, the system status of being out-of-stock when demand occurs leads 
to loss in terms of lost sales (perhaps, even loss of a regular customer), reduced sales etc. All these 
come under the heading of shortage costs (Wagner, 1974). In the immune system, shortage level 
can be interpreted as the number of unbound antigens left in the system (whether or not a sufficient 
number of antibodies i available to bind them) when equilibrium is regained. If no such shortage 
will be tolerated by a normal immune system, the shortage l vel must be zero. The cost associated 
with a shortage would be in terms of the damage that the unbound antigen could cause to the 
body. Self-repair of the damage which might involve production of cells etc by the immune system, 
requires energy. Since energy will be diverted for this urgent ask, other bodily functions might 
suffer. Also, the presence of unbound antigens over a long period of time could lead, along with 
unwanted biochemical interactions and energy consumption, to tolerance of the antigens. Some 
quantitative measure of these types of factors would represent the shortage cost in this inventory 
model. 
Some economic inventory models include a "set-up" cost, which consists of the cost of setting 
up machinery and the carrying out of administrative r quirements in order to start production. 
Primary immune response (i.e. response to an hitherto unknown antigen) is observed to be slower 
than secondary responses (Mohler et al., 1980). The slow first response could be because the 
required antibody is not available in the inventory and must be produced afresh, under the current 
environment, which will incur an extra "cost" in terms of biochemical energy and other esources. 
The "costs" associated with this would be the set-up cost. Later responses either do not incur a 
set-up cost or incur reduced amounts of it. 
The actual production of goods also costs money, which constitutes the production cost. The 
physical resources and energy utilized for producing the antibodies would be considered in the 
production cost in the immune system inventory model. 
Every characteristic of the basic (production-and-) inventory model in econometrics has a 
counterpart in the antibody-response system in immunology. Predictor--corrector methods applied 
to the basic production-inventory model for an antibody in the immune system and to the 
resolution of the problem would lead to a better understanding of the way in which the immune 
system is maintained naturally. In the process, newer optimization techniques might be discovered, 
which could then be applied to improve the performance of some complex economic, engineering 
and other biological systems. 
2. FORMULATION OF THE PROBLEM 
With reference to the inventory system defined above, we now formulate the mathematical 
problem which could be analysed to seek possible answers to important questions which motivated 
us towards the present study. 
In this paper, we consider a single product (monoclonal ntibodies), isolated (non-interacting 
with other immune system components like, for example, anti-idiotypic antibodies), static (fixed 
optimality) system for "known" (secondary response) antigens pecific to the product. 
2.1. System Entities and Parameters 
The process begins at time t o (> 0) with the entry of antigens into the system and ends when 
equilibrium is regained at some time t~ > to. Initially (at time to) the system contains do f-valent 
antigens and I0 (free as well as B-cell-bound) g-valent antibodies. 
We define the other system entities at any time t (> to) as follows: 
and 
i ( t )  = 
D( t )  = 
Q( t )  = 
Ro(t)  = 
inventory level at time t, 
total demand at time t, 
number of antibodies produced uring the interval [to, t], 
number of antigens bound by antibodies during [to, t] 
Ao(t) = number of antibodies bound by antigens during [to, t] 
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Q, R0 and A0 are random variables with typical values q, r and a, respectively. 
Clearly, 
and 
i(t) = Io + q(t) - a(t) >f 0 
r(t) + d(t) = do = d(to). 
O) 
(2) 
2.1.1. Low-zone tolerance 
The fact that there is no immune response for a very small number of antigens uggests, on the 
one hand, that a certain number of unbound (by antibody) antigens (unsatisfied emand) will be 
tolerated by the system with no loss and, on the other, that a certain shortfall from the optimal 
inventory level is permitted in the system. Let these two critical values be al and ~2, respectively. 
In the present model, they are constants ince the optimum inventory level is constant by problem 
definition. 
The number of free antigens present in the system at time to will be a random variable, say, A, 
taking values 0, 1 . . . . .  ~1. Let P6 be the probability that A = 6, 6 = 0, 1 . . . . .  a,. Obviously, A is 
independent of to. 
Similarly, the actual shortfall from the optimum inventory level I at t o will be a random variable, 
say F, taking values 0, 1 . . . . .  a2. Hence, I0 will also be a random variable and is given by 
I0 = I - r .  (3)  
Clearly, F is independent of to. We define p* to be the probability that F = y, ~ = 0, 1 . . . . .  ~2. 
2.1.2. High -zone tolerance 
The number of antigens present in the system at time to is also a random variable, say, Do, and 
is given by 
Do = A + D~, (4) 
where D~ is the random variable representing the number of antigens that entered the system at 
time to. Given that A = 6, Do can take any of the values 6 + 1, 6 + 2 . . . . .  in most normal situations. 
However, when Do takes any value above the high-zone tolerance limit, the immune system will 
be paralysed; the shortage cost at that antigenic level will be infinite. We define fl to be the threshold 
value of Do, above which paralysis of the immune system occurs. In the present model,//wil l  be 
a constant because the optimum inventory level I is constant. We represent the probability that 
D1 =dl  by p(dl), d, = 1,2 . . . . .  
2.1.3. Time dependence 
For a mathematical nalysis of the present model, what interests us are the states of the system 
at time to and t~, and not their evolution over time interval (to, tt). Noting that q(t~), a(tl) and 
r(t~) are cumulative values over the interval [to, tl] and that, at equilibrium, they are independent 
of the time interval, we may drop the subscript in q(t), a(t) and r(t), and hence also in i(t) and 
d(t). 
2.2. Optimality Constraints 
A normal, healthy immune system behaves in a stochastically predictable manner, at the end of 
an immune response. Essentially, the number of free antibodies and free antigens in the system at 
equilibrium must lie within a range of values dictated by the low-zone tolerance limits. These 
translate as, 
(0 <) I  - a2 ~< (I -- y) + q - a ~< I (5) 
and 
do - r ~< aL. (6) 
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Since q, a and r in constraints (5) and (6) are typical values of random variables Q, A 0 and R0, 
respectively, conditions (5) and (6) can be incorporated into the problem by restricting the ranges 
of Q, A0 and R0 so as to satisfy these constraints. 
2.2.1. Optimal range for Ao 
From condition (5), we have, 
q -~  ~<a ~<q -y  +0t 2. (7) 
Further, since the antigens are f-valent, the binding constraint 
a ~< dof (8) 
should hold. 
For do lying within the responsive range, at least one antigen has to be bound, which means that 
at least one antibody has to be bound. Hence, 
a>/1 for d0~[~+l ,  fl]. (9) 
We are not interested in do > fl since the immune system loses control and ceases to behave ideally 
in this case. When do ~< ~,  it is possible that a = 0, in which case, r = 0, i.e. not only are no 
antibodies produced, but also no Ag-Ab binding occurs and the state of the system does not change 
so that t~ = to; this situation too is not particularly interesting. 
So, from constraints (7)-(9), we get 
a~ = max{l, q - y} ~< a ~< a2 = min{dof, q - y + ~2}. (10) 
Thus, the optimum permissible range for A 0 depends on parameters f and ~2, and on the values 
taken by the random variables Q, F and Do (Do ~< fl). 
2.2.2. Optimal range for Ro 
From binding conditions, we know that, given that a antibodies are bound, at least [[a/f]] and 
at most min{ga, do } antigens have to be bound. (We define [[x]] = positive integer just greater than 
or equal to x, x/> 0.) Combining these with optimality constraint (6), we get 
r~ = max{d0 - st, [[a/f]]} <~ r <~ r2 =- min{do,ga}. (11) 
2.2.3. Optimal range for Q 
Resource limitations give the condition (see Section 2.3.2 below) 
q <<. q* <~ [Y/c2]. (12) 
Further, in order that the range of A0 be non-empty, from constraint (10), we get 
q ~ d0f+ 7. (13) 
For do ~ [st + 1, fl], by definition, 
and, from constraint (11), 
from which we get, 
q i> 1 (14) 
do - ~t 1 <<. r <~ ga 
d0-0¢ 1 
q/> +~ --*t2. 
g 
Combining constraints (12)-(15), the range for Q comes out to be 
q, - -max{l ,  [ [~L~2] I  + , -  ~t2} ~< q <<.q2-min{dof+,,q*}. 
(15) 
(16) 
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For do ~ [0, Ctl] U (fl, oo), by definition of non-response, 
Q-0 .  
2.2.4. Critical value for high-zone tolerance 
Lemma. The critical value for high-zone tolerance is given by 
fl = g(q* + 0~ 2- -  ])) -[- 0~ I . (17) 
This result is obtained by applying the definition of fl to the condition that the range of Q given 
by condition (16) be empty. 
In the dynamic case, when optimal I can vary, ~2, and hence F, and hence, fl would also be 
dynamically variable. From equation (17), we also note that for constant g, q*, ~2 and ~, 
a change in the value of (x I would lead to a corresponding change in fl so that the difference 
( f l -  ~ l )= number of values of Do for which there is immune response, remains constant. An 
increase in antibody valency, permissible shortfall from the optimal inventory level or available 
resources for production would widen the range of values of the number of antigens which the 
immune system can tackle optimally. The situation improves further if there is no actual shortfall 
from the optimal inventory level. 
2.3. Costs Involved 
In reference to their definition and with the specification of the system entities above, we now 
formulate the expressions for various costs. 
As mentioned above, the notion of "costs" in the inventory model here is mainly associated with 
different kinds of energy imbalances and harmful effects (of unwanted or abnormal biochemical 
reactions) related with the biological analogue of this model. The measure of "costs" would 
therefore be based on the formation--enthalpies, valencies, thermodynamic parameters and 
activation rates etc. of related molecules, enzymes, reactions or biochemical media. Linear cost 
functions with per unit "cost" given in terms of the average quilibrium combination of these 
parameters (measured in calibrated form for one molecule of antigen or antibody) for different 
situations would thus reasonably re~resent the different kinds of costs being considered in this 
model. 
2.3. I. Holding cost 
As stated earlier, this cost is incurred due to the biochemical energy required to maintain 
antibodies and the loss due to unwanted interactions of these antibodies with other body 
components. Let C~ be the cost of holding one antibody for unit time. 
Since (I - F + Q - A0) antibodies are held in the system at time tt, the total expected holding 
cost is 
~t2 ¢tl fl q2 (a2, r2) 
~ ~ ~ X CI(I - ~: + q -- a)P,-r+q, do (a, r)pr.do(q)p(do -- 6)p~p*, (18) 
7=0 6=0 d0=6+l  q=ql (a,r)=(al,rl) 
where Pr, do(q) = Pr(q Abs are produced IF = y and Do = do), pl_r+q, ao(a, r) = Pr(a Abs and r Ags 
are bound [I - 7 + q Abs and do Ags are available) and the rest of the quantities are as defined 
earlier. 
2.3.2. Production cost 
This occurs in relation with the energy and other resources consumed for producing antibodies. 
Production occurs only when the number of antigens in the system lies in the range [cq + 1,/3]; 
otherwise, the production cost is zero. Since the limited energy available in the body is used for 
all vital physiological nd biochemical processes on a co-operative basis, the number of antibodies 
that can be produced would also be limited. Further, the production of too large a quantity of 
antibodies of a particular specificity would require an explosive chain reaction of antibody 
production to maintain antibody sites equilibrium. Taking all these factors into consideration, 
we limit production by imposing a "capital" constraint hat only Y price units are available 
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for production. Taking (72 to be the average per unit production cost, 
time-independent, the total expected production cost comes out to be 
~t2 Ctl fl q2 
E E E E C2qP~.do(q)pfdo - 6)p6p*. 
v=O 6=0 do=6+l  q=ql 
which is obviously 
(19) 
2.3.3. Shortage cost 
This cost arises when unbound antigen are present in the system. In fact, the shortage cost 
depends on: 
(i) Time--when an unbound foreign antigen is present in the body for a long 
period of time, the immune system learns to tolerate it, so that even when a 
concerted attack by the antigen occurs at a later date, it fails to defend the 
body. As such, the cost of shortage increases as the period of shortage 
increases. 
(ii) Quantity demanded--shortage cost in finite when the quantity demanded is
~< fl, but when do > fl, this cost becomes infinite at any t 1> 0. 
(iii) Quantity short--this dependence is obvious. 
As with all other system entities, we consider a shortage occurring at time tl and the shortage cost 
occurring per unit time at tl (it may be noted here that all left-over antigens have been present in 
the system for the same length of time). So, we need not consider the time dependence of the 
shortage cost. The total cost of shortage of, say, s units is averaged over the units to obtain the 
per unit shortage cost so that, if Csdo(S) = shortage cost for s units given the total demand was do, 
we have 
C~o(S)=SC,, 
where C, is the per unit analogue of shortage cost in a given situation (noting that the case of do > fl 
is not applicable to the present model, the per unit shortage cost per unit time becomes independent 
of do and is denoted by Cs). 
Hence, we have the following expression for the total expected shortage cost in this case: 
~ ~. C,(do - r)pt_,+q, do(a, r) p(do - 5)p6p*. (20) 
) '=0 6=0 do=6+l  L(a,r)=(al,rl) 
2.3.4. Total expected cost (TEC) 
We define the function, TEC (I; g,f, at, Y, C) to be the total expected (TE) cost for our inventory 
system, satisfying the optimality constraints for given parameter values g,f, 0t = (~tl, ~t2), Y and 
C = (C~, (72, C,). Let K = (g,f, at, Y, C). 
TEC(I; K) = TE holding cost + TE shortage cost + TE production cost 
= 2 ~ [C,(I-y +q-a)  
) '=0 6=0 do=6+ I q=ql ka=al  r=rl 
+ C,(do - r)]p,_r+q, do(a, r) + C2qtp~,do(q)p(d o 5)p~p* (21) I 
with the ranges of summations and other quantities as defined earlier by equations (10), (11), (16) 
and (17). Our aim is to find I for a given K, which minimizes the TEC(I; K) given by equation (21). 
Before that, we find expressions for the different probabilities to obtain a closed-form expression 
for TEC(I; K) so that its relation to I becomes clearer. 
3. PROBABILITY DISTRIBUTIONS 
Under normal conditions, on the basis of available knowledge about the processes associated 
with the stochastic aspects of the above-mentioned inventory system, we fit the most appropriate 
probability density functions to the random variables of this model. 
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3.1. Distributions of A and F 
Given the low-zone tolerance levels, a~ and as for antigens and antibodies, respectively, the 
number of free antigens A and the shortfall from the optimum inventory level, F, just before the 
start of the process (at time to), take values over 0, 1, 2 . . . . .  at and 0, 1, 2 . . . . .  as, respectively. The 
distributions of these random variables will be the same at any time t at which the system is at 
equilibrium; hence they are independent of the time point at which they are considered. Also, there 
is no reason to suppose that A and F will favour any one of their possible values over any other. 
Thus, it is reasonable to fit the uniform probability density functions to A and F: 
I 1 p~=Pr(A=6)= al+-----l' 6=0,1  . . . . .  al 
[ 0, otherwise (22) 
and 
I 1 
p* = Pr(F = y) = a2 5~ 1' 
( 0, 
Y = 0, 1 , . . . ,a2  
otherwise. (23) 
3.2. Distributions of D~ and Do 
D~ is the number of antigens that enter the system at t 0. Under most normal situations, the 
average rate of entrance of antigens per unit time under given external conditions, would be 
constant. Also, there is no interaction amongst the entering antigens (there are infinite entry points) 
and the number of antigens entering in non-overlapping intervals of time is statistically indepen- 
dent. Hence, the number D~ of newly arrived antigens would reasonably be distributed as a Poisson 
variate. 
In natural conditions, antigens appear near the immune system in "quantum" lots of varying 
sizes (e.g. antigens on a bacterium). While this appearance is instantaneous, it usually takes finite 
time for the antigens to "diffuse" into the immune system. Without loss of generality, we assume 
this length of time to be unit time. On this scale, we choose h to be a sufficiently small length of 
time during which an antigenic entry occurs with fixed probability 2t and more than one entry 
occurs with probability approaching zero. Further, as happens in many cases of infection, we 
assume that no further exposure to antigens occurs till after equilibrium of the immune system is 
regained at time tl. Since the case of no demand is of no interest here, we fit the truncated Poisson 
distribution 
e-~.2a, 
Pa, = Pr(Dl =d l )  =dl  !(1 - e-~') ' d l=  1, 2 . . . . .  (24) 
with 2 = 2~ h = expected number of antigens entering the system in unit time being constant. 
Finally, Do = A + Dt and 
Pr(Do = do) = ~ Pr(A = 6)Pr(Di = do - 6IA = 6) 
6 
"' e-~'2ao-rH(do - 6) 
=E d0= 1,2,3 . . . .  
~=o (do - 6)!(1 - e-:')(at + 1)' 
(25) 
since D l and A are independently distributed. Here H(x), which equals 1 for x > 0 and 0 for x ~< 0, 
is the unit step function. 
3.3. Distribution of Q 
The number of antibodies produced is directly proportional to the number of antigens in the 
system and also the shortfall from the optimal inventory level at initial time to. By definition of 
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low- and high-zone tolerance, the probability that q antibodies are produced, given F = ), and 
Do = do, is given by 
0, q ¢ 0 (26) 
Pr,do(q) = 1, q = 0 
for 
4e [o, ~,]u[~ + l, oo). 
When do lies in the responsive range, [0~ 1"4- 1, fl], the optimal number of antibodies produced has 
to be at least q~ and at most q2, as seen in Section 2.2.3. Since, a priori, any of these values of Q 
would do just as well as any other insofar as the immune response is concerned, we can say that, 
P~,do(q)= q2- -q l+ l '  q=q l ,q l+ l  . . . . .  q2 
O, otherwise (27) 
3.4. Joint density of  (Ao, Ro) 
The permissible range of values for A0 and Ro in a normal immune response are given by 
conditions (10) and (11). For a given set of parameter values, in the present case these ranges can 
be seen to depend on the values taken by the random variables Q, F, Do and Do, A0 respectively. 
Essentially, the dependence is on the number of antigens (say, G) and antibodies (A) present in 
the system. So, we define, p~.~(a, r) to be the joint density of the probability that A0 = a and R 0 = r, 
given A and G. 
The event of "a"  g-valent antibodies and " r "  f-valent antigens being bound can occur in a 
number of mutually exclusive ways (Chandrika and Joshi, 1989): there can be 1, 2 . . . .  min{a, r} 
immune complexes containing a total of a bound antibodies and r bound antigens. Given that an 
Ag-Ab aggregate contains a0 antibodies, the number of antigens, r0, binding them together must 
satisfy the condition imposed by the valencies (Chandrika, 1987): 
[[(a0 - 1 ) / ( f -  1)]] ~< r0 ~< a0(g - 1) + 1. (28) 
Potentially, the event that there are k "cells" containing a total of a antibodies, can occur in as 
many different (mutually exclusive) ways as there are "partitions" of the positive integer a, of length 
k, i.e. the number of different ways in which the positive integer "a"  can be represented as 
a =aL+a2+' ' '+ak ,  
where a, (i = 1, 2 , . . . ,  k) are positive integers and the unordered set (a~, a2 . . . . .  ak) is counted only 
once. For example, for k = 2, a = 5 can be represented in exactly two distinct ways. Since each 
of these k cells must also contain antigens, and the number of antigens in a cell can vary according 
to condition (28), the number of ways in which the event of a antibodies and r antigens being bound 
can occur is combinatorially arge. From all these considerations, we obtain: 
PA.G(a, r) = Pr(a Abs boundlA, G) 
x Pr(r Ags boundlA, G, a Abs bound) 
~- )~r  ) WI0 W01 i _2~1 )_2~1 a!r!.n=FIl am]rjn]Wam'rln " (29) 
Here, i, = number of distinct partitions of a, j, = number of partitions of r which "match" the ith 
partition of "a"  with respect o condition (28); w 0 = Pr(a randomly chosen immune complex from 
amongst all those present in the equilibrium state at the end of an immune response, contains i 
antibodies and j  antigens); a; = (a,1, an . . . . .  aia) is the ith distinct partition of a, of length ~< a, and 
similarly r~ = (r~, rj2 . . . . .  r~). An assumption made in the above derivation is that B-lymphocyte- 
bound antibodies behave in the same way as antibodies in the fluid state. 
The weight fraction (or aggregate size) distribution, (wo), has been obtained (Macken and 
Perelson, 1985) by the use of two-type branching processes under different conditions. For instance, 
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under the assumptions of no cyclic aggregates being formed, equal reactivity of all antigen sites 
(and all antibody sites), the probability of a randomly chosen "root" of a branched tree being an 
antibody being A/(A + G), and non-gelation, Macken and Perelson (1985) have obtained the 
aggregate size distribution as 
W,o={A- -~(1- r , ,p ) ' ,  i= l  
O, i/> 2' (30a) 
0, j >/2 (30b) 
= G Wo: (1 - -p) f  j = 1 
and 
fGr~- ' ( i+ J ) ( (g -1 ) i~( ( f - l l ) J  ) 
w,j= (A + G)ij 1 ,I\ i - 
×(1-rjp)~-°'-l+l(1-p)(f-t~-'+]p'+J-~, i>~ l, j>>. l, (30c) 
where p = Pr(a randomly chosen antigen site is bound), r I = ratio of antigenic sites to antibody 
sites = (fG/gA). In our model, A = I - y + q and G = do. All assumptions made in the derivation 
of w,j are also inherited by our model. 
4. ANALYSIS FOR OPTIMAL INVENTORY 
In order to analyse the model of interest, we shall now consider the cost expressions after 
replacing the associated probability terms by the appropriate xpressions for them, as obtained in 
Section 3 above. We now have, 
TEE(I; K) = E E E E S[Cl( I  - 7 + q -- a) 
y=0 6ffi0 d0ffidi+ 1 kq=qla=alr=rl 
¢. ( I  - + q)!do! + Cs(do r)] I ,= , ,= , ( I - -y -+-q - - -~- - r ) [L '  L, 
>( WIO '+q-awod~-" Wam'rm ~+ C2q 
a,n!rjn!] (do-~)! 
(1 -- e-;') -]  
x (31) 
(q2 - q~ + 1)(ct~ + 1)(~ 2 + l) 
with w,j (i,j = 0, 1 . . . .  ) being given by equations (30a-c); S being the normalizing factor for Ag-Ab 
binding probabilities and other quantities being as defined earlier. 
4.1. Lower Bound for the Optimal Inventory Level 
The term (1 -p fG/gA)  occurring in the expression for w,~ [equation (30a)] is obtained after 
equating the expected numbers of bound antigen and antibody (Macken and Perelson, 1985). In 
fact, the quantity p(fG/gA) is equal to the probability that a randomly chosen antibody site is 
bound. Therefore, substituting G = do and A = I - ~, + q, we should have, for given parameter 
values f ,  p and g, 
fdoP 0< <1,  
g(I-- y + q) 
from which we get 
I >J-vPfd~ _ q + ~, (32) 
g 
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and this relation must hold for all permissible values of do, q and y. In particular, 
I>max~fdoP--q+Y}do.~.q( g (33) 
assures us that the condition is satisfied Vdo, q, 7. Successively maximizing the r.h.s, of inequality 
(33) over q, do and 7, we obtain a lower bound for I as a function of the parameters of the model, 
namely 
0t I I>max{fp(~+ 1)+~t2--1, fp(~ +ct2+ 1) -1 ,  fp(q*+--+~2)--q*,~t2}.g (34) 
We seek to find the value of i which minimizes the objective function (31) subject o the feasibility 
constraint (34). 
Since the wvs are also functions o f / ,  expression (31) for TEC is highly non-linear in L The 
properties of TEC (/ ,-)  as a function of I is not immediately clear; all we can say is that it is 
probably not a monotone function of I and multiple solutions to the optimization problem might 
exist. 
We resort to numerical techniques to find a solution to the problem. 
4.2. Variation of Parameters and Applied Results 
To illustrate the application of the antibody inventory model and analysis in a predictive and 
explanatory sense, we have obtained the solutions for the optimal inventory level with variation 
in parameters. These results are presented in Table 1. 
4.2.1. Effect of variation in ~, and ~t 2
The relative values of ct  and at 2 play a crucial role in determining the immunocompetence of the 
system. 
Consider a system with ~q = g2 = 0. This would mean that no free antigen will be tolerated by 
the system and no shortfall from the optimum inventory level will be allowed to occur. All the 
antibodies that are produced uring a response must get bound to all the antigens that have entered 
the system. If any more antibodies get bound, it might lead to an immunodeficient state. Since 
~, = 0, in this case, TEC(I) will be linear in I and hence the optimum value of I,/opt, will be Imm 
(sets Do-D 3 in Table 1). 
In a situation where fcq > or2, the total number of tolerable antigen sites exceeds the total 
permissible shortfall in the optimum inventory level. In this case, it may so happen that ~t 2 
antibodies get bound but some antigens continue to be tolerated although the inventory level has 
dwindled to Iopt - ~t2; if any of these antigens gets bound, the inventory level ceases to be within 
optimal bounds and, by definition of g~, no antibodies will be produced to compensate for the loss. 
Such a situation would lead to immunodeficiency in the corresponding system. If aq > gGt2, the 
chances of its occurrence becomes even greater (set D4, Table 1). As p increases, so does the 
tendency for immunodeficiency in this case (sets Ds, D6, D7, DI2 and DH in Table l). A real system 
having parameter values as given in set D 7 would be more prone to immunodeficiency than one 
for set D 6 . 
Table 1. Some parameter sets for g = 2, f= 4 and 2 = 2 and computed TEC values for 
minimum feasible I; for sets Do-D 3, Ira, n is the optimal value of I 
Set Y C 1 C 2 C, p a I ~t 2 Imm TEC 
D o 50.0 2.0 5.0 6.0 0.14 
D t 50.0 2.0 4.0 6.0 0.14 
D 2 50.0 2.0 5.0 6.0 0.6 
D 3 50.0 2.0 5.0 6.0 0.01 
D 4 50.0 2.0 5.0 6.0 0.14 
D~ 50.0 2.0 5.0 6.0 0.14 
D 6 50.0 2.0 4.0 6.0 0.14 
D7 50.0 2.0 5.0 6.0 0.6 
D~ 50.0 2.0 5.0 6,0 0.01 
D 9 50.0 3.0 5.0 6.0 0.14 
Di0 50.0 3.0 6.0 7.0 0.14 
Dll 50.0 2.0 5.0 6 0 0.14 
Dr2 50.0 2.0 5.0 6.0 0.01 
1 2.22224 
1 2.21126 
10 25.77482 
1 2.22419 
1 2.97981 
2 6.37214 
2 6.15326 
13 30.83604 
2 7.58858 
2 8.21454 
2 9.07129 
3 7.49821 
3 9.58992 
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When f0q < 0t2, even if all the tolerated antigens get bound, the inventory level will remain above 
its lower bound for optimality. The full amount of shortfall permitted in the inventory level will 
not be utilized in such a system. This suggests that such a choice of'~2 by an immune system will 
not be optimal. Back-interpretation f "costs" in this case suggests that the /opt level maintained 
by such a system should ideally be less than/opt values for another system with similar cost tolerance 
but with fcq not less than 0t 2. 
Supposefcq = et 2 . In this case the system has enough antibodies to bind all the sites on tolerated 
antigens without loss of optimality in the inventory level; at the same time, it allows for just enough 
such antibodies o that the system can make use of the full permitted amount of shortfall in the 
inventory level. 
4.2.2. Effects of cost rates and Y 
Other parameter values being the same, if the per unit holding cost were to be increased (sets 
D~ and 0 9 in Table 1) the TEC at each feasible value of I will increase. Consequently, TEC(new 
/opt) will be ~>TEC(old/opt). If 0t I = 0, the change at each I will be linear and the new/opt  will be 
the same as the old/opt and each equals Im,n. 
As the per unit production cost increases (sets D~, Do, D 6 and D5 in Table 1) the system's 
capacity for producing antibodies falls and so does fl, the upper response limit for antigens. 
The former would tend to increase the values of/opt, while the latter tries to lower it. The 
actual relation of the new /opt with the old /opt will depend on which of the two effects is 
dominant. 
When Y increases, the maximum resource available for producing antibodies, increases. The 
range of values of do for which there is an immune response, widens, which means that the new 
system has to be prepared to successfully deal with larger numbers of antigens. On the other hand, 
since the system's capacity for antibody production has increased, the system can afford to hold 
fewer antibodies in the inventory. The final effect on/opt of a change in Y will be a superimposition 
of these two effects. 
Changes in the per unit shortage cost play much the same role as those in the per unit holding 
cost when cq > 0. When 0q = 0, the shortage cost in TEC is zero. 
4.2.3. Effect of variation of p on lop, 
The influence of the probability p that a randomly chosen antigen site is bound in relation to 
the variations in 0q and ct 2 is discussed in Section 4.2.1 above. It also affects TEC(.) through the 
aggregate size distribution. As p increases the tendency is for larger aggregates to form. The 
probability that an antibody is free decreases. Consequently, the system should keep more 
antibodies in stock to cope with the increased loss of antibodies due to the greater affinity between 
antigen and antibodies. 
In sets 0 3 and Do (Table 1), the value of/opt remains the same because /opt = Im,n = 0~2 + 1. But 
one may note that it becomes more expensive, on average, for the system to persist with the same 
inventory level. When p increases ignificantly (sets Do and D 2 in Table 1) it can be seen that/opt 
increases. 
4.2.4. Significance of optimal cost factors 
For a given set of parameters applicable to a healthy system, let the expected holding, shortage, 
production and total costs at I =/opt be H*, S*, P* and T*, respectively. 
Any system with the same parameter values which can bear (due to some other random, external 
causes and energy conservation, for instance) a maximum holding cost of H < H* and production 
cost of Y < P* will be relatively antibody deficient. It will be more likely to be paralysed by an 
antigenic attack. On the other hand, a system which can bear H > H*, Y > P* and minimum 
TEC > T*, possibly has "too many" antibodies, some of which might turn autoreactive in the long 
run. Similarly, a system which can bear a shortage cost of S > S* would be more prone to 
tolerating free antigens. 
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5. DISCUSSION 
The functional adaptivity and stability required by life is maintained through an extensive 
number of intermediate and allosteric enzymatic control mechanisms. In an organism (or even at 
cellular level) an optimal metabolic pathway is chosen, which optimally utilizes substrates and 
energy by reducing power with different stochiometric couplings, leading to different products and 
energy with reduced power yield factors. The energetics of bioconversion and other biochemical 
reactions are thus most important for regulating various ub-systems such as the immune system. 
This poses interesting problems regarding the control of the immune response under optimal energy 
utilization. 
For instance, the lymphocytes for producing antibodies of a particular specificity might be either 
inherited from the parents by the preimmune system, or innovated by the individual's own immune 
system in response to an immediate need for it. In the latter case biochemical energy and other 
resources would be required for the process of discovery, starting from an existing, approximately 
matching, antibody type for the given antigen. Some principle of optimizing the resource usage, 
under given environmental conditions, could be a crucial factor in determining the specific immune 
components hat are transmitted from generation to generation, and thereby, also play a decisive 
role in the course of evolution. A multitype inventory model based on that presented in this paper 
could help in clarifying some such complex questions. 
Our approach in this paper involves "costs" to represent the role of energetics of the major 
biochemical processes associated with antibody production and maintenance in the equilibrium 
state during immune response. The limited data on Gibbs free energy functions and thermodynamic 
parameters ofmany known biochemical reactions may limit the exact evaluation of cost parameters 
for implementing our model on real experimental systems. However, as illustrated in our analysis, 
results and interpretations, it is the qualitative difference in parameter values which is useful for 
predicting or explaining the behaviour of unhealthy (e.g. immunodeficient or potentially auto- 
immune) immune systems as compared to an ideal healthy system involving the same antigens and 
antibodies. 
The consideration of optimal utilization of biochemical energy for understanding some aspects 
of the immune system, as proposed here, would offer newer directions to multidisciplinary research 
in immunology. Finding an efficient algorithm for global optimization i  the integer space of a 
highly nonlinear function like TEC(I) in equation (31) should be a problem of significance in the 
computational domain also. 
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